INS and fatty liver disease: Experimental evidence based on both human hepatocytes and animal models also suggests that GLP-1 RAs are able to improve hepatic steatosis by reducing de novo lipogenesis, enhancing oxidation of fatty acids and improving multiple elements of the insulin signaling pathways [52,53,54,55,56].